Risk prediction models of breast cancer: a systematic review of model performances Thunyarat AnothaisintaweeYot TeerawattananonAmmarin Thakkinstian Review 11 November 2011 Pages: 1 - 10
Role of interleukin-10 in breast cancer HamidullahBendangla ChangkijaRituraj Konwar Review 05 November 2011 Pages: 11 - 21
Ultrasonographic differentiation of malignant from benign breast lesions: a meta-analytic comparison of elasticity and BIRADS scoring Gelareh SadighRuth C. CarlosBen A. Dwamena Review 05 November 2011 Pages: 23 - 35
A diagnostic gene profile for molecular subtyping of breast cancer associated with treatment response Oscar KrijgsmanPaul RoepmanAnnuska M. Glas Preclinical Study 04 August 2011 Pages: 37 - 47
Co-expression of SNAIL and TWIST determines prognosis in estrogen receptor–positive early breast cancer patients Johanna G. H. van NesEsther M. de KruijfJohn M. S. Bartlett Preclinical Study 28 July 2011 Pages: 49 - 59
Targeted and intracellular triggered delivery of therapeutics to cancer cells and the tumor microenvironment: impact on the treatment of breast cancer Vera MouraManuela LacerdaJoão N. Moreira Preclinical Study 30 July 2011 Pages: 61 - 73
Inhibition of aldehyde dehydrogenase (ALDH) activity reduces chemotherapy and radiation resistance of stem-like ALDHhiCD44+ human breast cancer cells Alysha K. CrokerAlison L. Allan Preclinical Study 05 August 2011 Pages: 75 - 87
Oxidative stress and hematological profiles of advanced breast cancer patients subjected to paclitaxel or doxorubicin chemotherapy C. PanisA. C. S. A. HerreraR. Cecchini Preclinical study 03 August 2011 Pages: 89 - 97
The tamoxifen metabolite norendoxifen is a potent and selective inhibitor of aromatase (CYP19) and a potential lead compound for novel therapeutic agents Wenjie Jessie LuCong XuDavid A. Flockhart Preclinical study 04 August 2011 Pages: 99 - 109
RAD50 and NBS1 are not likely to be susceptibility genes in Chinese non-BRCA1/2 hereditary breast cancer Min HeGen-Hong DiZhi-Ming Shao PRECLINICAL STUDY 03 August 2011 Pages: 111 - 116
Enhancement of doxorubicin cytotoxicity of human cancer cells by tyrosine kinase inhibition of insulin receptor and type I IGF receptor Xianke ZengHua ZhangDouglas Yee Preclinical study 18 August 2011 Pages: 117 - 126
Physical activity and breast cancer survival: an epigenetic link through reduced methylation of a tumor suppressor gene L3MBTL1 Hongmei ZengMelinda L. IrwinHerbert Yu Preclinical study 12 August 2011 Pages: 127 - 135
Anti-tumor effects of a novel retinoic acid metabolism blocking agent VN/14-1 in the N-methyl-N-nitrosourea-induced rat mammary carcinoma model and its effects on the uterus Paul E. GossShangle QiVincent C. O. Njar Preclinical Study 14 August 2011 Pages: 137 - 144
Alteration of Y-box binding protein-1 expression modifies the response to endocrine therapy in estrogen receptor-positive breast cancer Tokiko ItoShinobu KamijoKen-ichi Ito Preclinical Study 24 August 2011 Pages: 145 - 159
Genetic heterogeneity in HER2 testing may influence therapy eligibility Barbara BernasconiAnna Maria ChiaravalliMaria Grazia Tibiletti Preclinical Study 08 September 2011 Pages: 161 - 168
Histologic findings in normal breast tissues: comparison to reduction mammaplasty and benign breast disease tissues Amy C. DegnimDaniel W. VisscherLynn C. Hartmann Preclinical Study 01 September 2011 Pages: 169 - 177
Expressions of individual PHDs associate with good prognostic factors and increased proliferation in breast cancer patients Emmi PeuralaPeppi KoivunenArja Jukkola-Vuorinen Preclinical study 30 August 2011 Pages: 179 - 188
Smac-mimetic compound SM-164 induces radiosensitization in breast cancer cells through activation of caspases and induction of apoptosis Dong YangYongchao ZhaoYi Sun Preclinical study 07 September 2011 Pages: 189 - 199
Role of Src in breast cancer cell migration and invasion in a breast cell/bone-derived cell microenvironment Brant PohorelicR. SinghA. Magliocco Preclinical study 06 September 2011 Pages: 201 - 214
Erratum to: Role of Src in breast cancer cell migration and invasion in a breast cell/bone-derived cell microenvironment Brant PohorelicR. SinghA. Magliocco Erratum 11 October 2011 Pages: 215 - 216
Inhibition of EGFR phosphorylation in a panel of human breast cancer cells correlates with synergistic interactions between gefitinib and 5′-DFUR, the bioactive metabolite of Xeloda® Maria Ait-TihyatyZakaria RachidBertrand J. Jean-Claude Preclinical Study 14 September 2011 Pages: 217 - 226
Health-related quality of life, psychological distress, and adverse events in postmenopausal women with breast cancer who receive tamoxifen, exemestane, or anastrozole as adjuvant endocrine therapy: National Surgical Adjuvant Study of Breast Cancer 04 (N-SAS BC 04) Hiroyuki TakeiShozo OhsumiYasuo Hozumi Clinical trial 11 January 2012 Pages: 227 - 236
Dose-dependent change in biomarkers during neoadjuvant endocrine therapy with fulvestrant: results from NEWEST, a randomized Phase II study Irene KuterJulia M. W. GeeNadia Harbeck Clinical trial 28 January 2012 Pages: 237 - 246
Small node-negative (T1b-cN0) invasive hormone receptor-positive breast cancers: Is there a subpopulation that might have benefit from adjuvant chemotherapy? Yeon Hee ParkSeock-Ah ImYoung-Hyuck Im Clinical trial 21 January 2012 Pages: 247 - 255
Prognostic impact of placenta growth factor and vascular endothelial growth factor A in patients with breast cancer Else MaaeDorte Aalund OlsenAnders Jakobsen Clinical Trial 22 January 2012 Pages: 257 - 265
Prospective study of breast tomosynthesis as a triage to assessment in screening Daniela BernardiStefano CiattoNehmat Houssami Clinical trial 22 January 2012 Pages: 267 - 271
Characterization of four novel BRCA2 large genomic rearrangements in Spanish breast/ovarian cancer families: review of the literature, and reevaluation of the genetic mechanisms involved in their origin Gorka Ruiz de GaribaySara Gutiérrez-EnríquezMiguel de la Hoya Epidemiology 21 March 2012 Pages: 273 - 283
Black–white differences in receipt and completion of adjuvant chemotherapy among breast cancer patients in a rural region of the US Joseph LipscombTheresa W. GillespieKevin C. Ward Epidemiology 26 January 2012 Pages: 285 - 296
Disparities in breast cancer care delivery: solving a complex puzzle Christopher R. Friese Invited Commentary 08 March 2012 Pages: 297 - 299
Incidence of reduced chemotherapy relative dose intensity among women with early stage breast cancer in US clinical practice Derek WeyckerRich BarronGary H. Lyman Epidemiology 24 January 2012 Pages: 301 - 310
Higher expression of androgen receptor is a significant predictor for better endocrine-responsiveness in estrogen receptor-positive breast cancers Seho ParkHyung Seok ParkByeong-Woo Park Epidemiology 10 January 2012 Pages: 311 - 320
Favorable outcome associated with an IGF-1 ligand signature in breast cancer Lina MuDavid TuckHerbert Yu Epidemiology 02 February 2012 Pages: 321 - 331
Structural/organizational characteristics of health services partly explain racial variation in timeliness of radiation therapy among elderly breast cancer patients Stephanie B. WheelerWilliam R. CarpenterAndrea K. Biddle Epidemiology 22 January 2012 Pages: 333 - 345
Assessing the added value of breast tumor markers in genetic risk prediction model BRCAPRO Swati BiswasNeelam TankhiwaleBanu Arun Epidemiology 21 January 2012 Pages: 347 - 355
Willingness to use tamoxifen to prevent breast cancer among diverse women Celia Patricia KaplanSue E. KimEliseo J. Pérez-Stable Epidemiology 07 February 2012 Pages: 357 - 366
Adherence and discontinuation of adjuvant hormonal therapy in breast cancer patients: a population-based study Annette WigertzJohan AhlgrenMats Lambe Epidemiology 28 January 2012 Pages: 367 - 373
Social networks, social support and burden in relationships, and mortality after breast cancer diagnosis Candyce H. KroenkeYvonne MichaelBette J. Caan Epidemiology 14 February 2012 Pages: 375 - 385
Pregnancy occurring during or following adjuvant trastuzumab in patients enrolled in the HERA trial (BIG 01-01) Hatem A. Azim Jr.Otto Metzger-FilhoMartine Piccart-Gebhart Brief Report 26 February 2012 Pages: 387 - 391
Evaluation of RAD51C as cancer susceptibility gene in a large breast-ovarian cancer patient population referred for genetic testing K. De LeeneerM. Van BockstalK. Claes Brief Report 28 February 2012 Pages: 393 - 398
Not so fast: the use of incomplete data to devalue the role of mammography screening Daniel B. Kopans Letter to the Editor 14 February 2012 Pages: 399 - 399
Erratum to: Pathways mediating the effects of cannabidiol on the reduction of breast cancer cell proliferation, invasion, and metastasis Sean D. McAllisterRyuichi MurasePierre-Yves Desprez Erratum 22 March 2012 Pages: 401 - 404
